We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Global IVD Market to Reach USD 77 Billion by 2023

By LabMedica International staff writers
Posted on 12 Sep 2018
Print article
The worldwide market for in vitro diagnostic tests is estimated at USD 65 billion in 2018 and is expected to grow 4% annually to USD 77.8 billion by 2023, driven by the aging world population and stream of new test innovations, offset by reimbursement cuts globally and slower buying in the mature sectors.

These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

In 2018, the traditional core lab test segments – chemistry/immunoassay, hematology and coagulation – comprised 43% of the dollar value of the IVD market and about 65% of the market test wise. However, the growing importance of molecular, infectious disease and cancer tests will lead to the market share of these core tests declining to 43% in 2023.

A growing aging population, increasing procedures and test improvements will continue to drive the growth of the global market for in vitro diagnostic tests, although a number of factors will act as a constraint to market growth. Over the next five years, a slowdown in instrument purchasing decisions, impact of the PAMA legislation in the US, cold markets in Europe, reduction in reimbursement for glucose and low-cost competition (in an essential IVD market), migration of previously low volume tests to integrated analyzers (that bring down the cost per test), and consolidation of lab customers will hamper market growth.

"More testing, more patients, new types of tests and platforms balanced by wary governments and payors," said Bruce Carlson, Publisher of Kalorama Information. "Growth was as high as 7% when we did our edition 15 years ago. Will this be possible in the future? It is possible; watch the potential of sequencing and personalized medicine testing is fully seen that such rates might return. But right now, you are seeing stable moderate growth."

"Both customers in the labs and vendors in the IVD industry are combining around for more efficiency," added Carlson. "Customers are focused on where growth is and right now that is in testing for cancer and testing for infectious disease."

Related Links:
Kalorama Information

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.